How much has Medicare Part D spending on GLP-1 drugs grown since 2020?
How much has Medicare Part D spending on GLP-1 drugs grown since 2020?
Medicare Part D gross spending on GLP-1 drugs went from $7.22 billion in 2020 to $27.90 billion in 2024, about 3.9 times as much, summing the 13 GLP-1 brand rows in CMS’s Medicare Part D Spending by Drug data. CMS’s figures are before manufacturer rebates, which it does not publish.
All GLP-1 brands, by year
| Year | Spending, all GLP-1 brand rows | Claims, all GLP-1 brand rows |
|---|---|---|
| 2020 | $7.22 billion | 6,018,487 |
| 2021 | $10.19 billion | 7,885,425 |
| 2022 | $14.21 billion | 10,406,887 |
| 2023 | $22.61 billion | 16,553,308 |
| 2024 | $27.90 billion | 22,164,471 |
By ingredient
| Ingredient | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Semaglutide | $1.53 billion | $3.08 billion | $5.60 billion | $10.86 billion | $15.16 billion |
| Tirzepatide | No data | No data | $144.0 million | $2.36 billion | $6.34 billion |
| Liraglutide | $1.90 billion | $1.76 billion | $1.56 billion | $1.32 billion | $329.0 million |
| Dulaglutide | $3.28 billion | $4.70 billion | $6.23 billion | $7.36 billion | $5.45 billion |
| Exenatide | $313.8 million | $417.2 million | $382.6 million | $304.7 million | $231.2 million |
| Insulin glargine and lixisenatide | $121.4 million | $165.6 million | $215.9 million | $303.0 million | $300.2 million |
| Insulin degludec and liraglutide | $71.9 million | $75.8 million | $78.0 million | $91.4 million | $91.3 million |
By brand
| Ozempic | Semaglutide | $1,455,812,267 | $2,621,694,348 | $4,628,160,643 | $9,194,048,435 | $12,970,296,347 |
| Rybelsus | Semaglutide | $73,444,409 | $454,563,823 | $974,894,470 | $1,665,906,943 | $1,890,082,026 |
| Wegovy | Semaglutide | No data | No data | No data | $199,774 | $301,283,291 |
| Mounjaro | Tirzepatide | No data | No data | $144,035,152 | $2,361,384,157 | $6,336,942,641 |
| Zepbound | Tirzepatide | No data | No data | No data | No data | $387,343 |
| Victoza 3-Pak | Liraglutide | $1,545,815,415 | $1,422,292,583 | $1,238,594,872 | $1,004,635,145 | $203,063,050 |
| Victoza 2-Pak | Liraglutide | $349,476,159 | $334,897,957 | $319,205,509 | $317,213,565 | $77,832,721 |
| Liraglutide | Liraglutide | No data | No data | No data | No data | $48,095,824 |
| Trulicity | Dulaglutide | $3,284,873,062 | $4,702,174,724 | $6,225,291,668 | $7,363,856,224 | $5,454,134,725 |
| Bydureon Bcise | Exenatide Microspheres | $266,160,951 | $379,243,467 | $355,078,758 | $284,056,759 | $215,354,678 |
| Byetta | Exenatide | $47,676,632 | $37,988,662 | $27,500,961 | $20,645,626 | $15,877,480 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | $121,393,843 | $165,620,858 | $215,943,202 | $302,998,642 | $300,185,496 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | $71,921,892 | $75,755,898 | $77,994,459 | $91,415,961 | $91,255,682 |
CMS describes the Part D figures this way, in its catalog entry for the dataset:
“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
“The Part D spending metrics do not reflect any manufacturers’ rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
Spending changes with the number of people using a drug, the number of claims and the price per unit; CMS’s file reports each, and the brand table on the spending page shows claims and beneficiaries for 2024. This page does not say why spending changed.
Common questions
Which GLP-1 brand had the highest Part D spending in 2024?
Ozempic, at $12.97 billion in 2024, per CMS’s Medicare Part D Spending by Drug data.
Does CMS publish Part D spending for 2025 yet?
CMS’s Medicare Part D Spending by Drug file read Nov 15, 2026 covers 2020 to 2024.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.